BioXcel Therapeutics Inc. priced an offering of 2,303,030 common shares at $8.25 apiece to raise about $19 million gross proceeds.
The New Haven, Conn.-based biopharmaceutical company granted the underwriters an option to buy up to 345,454 additional common shares in the offering.
The transaction is expected to be completed Sept. 30, subject to customary closing conditions.
BMO Capital Markets Corp. is acting as book-running manager for the offering, with ThinkEquity as co-manager.
